The purpose of this study is to evaluate the efficacy and safety of remimazolam besylate compared to propofol for sedation in critically ill patients with deep sedation.
This is a single-center, prospective, randomized, controlled study using remimazolam besylate and propofol for sedation in critically ill patients with deep sedation. Subjects are randomized to remimazolam group and propofol group in a 1:1 ratio. Remifentanil is administered as the analgesic. Efficacy and safety profiles of remimazolam besylate are to be evaluated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
sedation drugs
Propofol
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
RECRUITINGThe percentage of time in the target sedation range without rescue sedation
The percentage of time in the target sedation range without rescue sedation
Time frame: From the beginning of using study sedatives until being discharged from our ICU, the sedation target was changed, 48 hours after enrollment, or dead, whichever came first
Adverse events
Adverse events
Time frame: From the beginning of using study sedatives until being discharged from our ICU, the sedation target was changed, 48 hours after enrollment, or dead, whichever came first
7-day ventitlator free time
7-day ventitlator free time
Time frame: From start of study to 7 days
Extubation at day 7
Extubation at day 7
Time frame: From start of study to 7 days
Length of ICU stay
Length of ICU stay
Time frame: From start of study to 28 days
28-day mortality
28-day mortality
Time frame: From start of study to 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.